The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRTH-101: An investigational treatment for thoracic solid tumors targeting discoidin domain receptor (DDR1) and the tumor microenvironment (TME).
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Biocartis; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; Go Therapeutics; GT Aperion; Guardant Health; Harbinger Health; Illumen; Incyte; Jazz Pharmaceuticals; Kivu Biosciences; Lengo Therapeutics; LigaChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Sanofi; Seagen; SystImmune; Tallac Therapeutics; Tempus; Theratechnologies; Vir Biotechnology; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); PUMA Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC); Physicans' Education Resource
 
So Yeon Kim
Consulting or Advisory Role - Boehringer Ingelheim; Genentech; Revolution Medicines
Research Funding - Abbvie (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); Bioinvent (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Bristol Myers Squibb Foundation (Inst); DynamiCure Biotechnology (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); MediLink Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Synthekine (Inst); Takeda (Inst); Vaccibody (Inst)
 
Shiraj Sen
Consulting or Advisory Role - Bayer; Guardant Health
Travel, Accommodations, Expenses - Bayer; Guardant Health
 
Christopher Nabel
Stock and Other Ownership Interests - OPKO Health
Patents, Royalties, Other Intellectual Property - Cambridge Epigenetix; ThermoFisher (Formerly Life Technologies)
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - IQvia; Next Oncology; Texas Oncology/US Oncology
Consulting or Advisory Role - Abbvie; Cartography Biosciences; Nimbus Therapeutics; Revolution Medicines
Research Funding - Abbvie (Inst); Acrivon Therapeutics (Inst); ADC Therapeutics (Inst); Alentis Therapeutics (Inst); Aprea Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo Therapeutics (Inst); Axion Bio (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cartography Biosciences (Inst); Compugen (Inst); DAAN Biotherapeutics (Inst); Daiichi Sankyo (Inst); Day One Biopharmaceuticals (Inst); Dewpoint Therapeutics (Inst); Dicerna (Inst); DualityBio (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Pharmaceutical (Inst); Hansoh (Inst); IconOVir Bio (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); IMPAC Medical Systems (Inst); Incendia Pharmaceuticals AB (Inst); Incendia Pharmaceuticals AB (Inst); Ipsen (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Normunity (Inst); Novo Nordisk (Inst); OBI Pharma (Inst); OncoResponse (Inst); Pfizer (Inst); ProteinQure (Inst); Revolution Medicines (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Symphogen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Tyligand Bioscience (Inst); VelaVigo Pharma Co (Inst); Vincera Pharma/Vincerx Pharma (Inst); Vividion Therapeutics (Inst); ZielBio (Inst); Zymeworks (Inst)
 
Rachel Sanborn
Honoraria - Curio Science; Illumina; OncLive/MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; IDEOlogy Health; Illumina; InhibRx; Janssen Oncology; Johnson & Johnson/Janssen; Lilly; Natera; OSE Immunotherapeutics; Pfizer; Rigel; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck
Travel, Accommodations, Expenses - Hotspot Therapeutics
 
Aparna Parikh
Stock and Other Ownership Interests - CADEX Genomics; OneCell Diagnostics India; Parithera; X genomes
Consulting or Advisory Role - 3T BioSciences; Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; CareSet; Caris Life Sciences; Checkmate Pharmaceuticals; CVS; Delcath Systems; DoMore Diagnostics; Exact Sciences; Foundation Medicine; GlaxoSmithKline; Guardant Health; Illumina; Incyte; Lilly; Merck; MPM Capital; Natera; Pfizer; Phesi; Regeneron; SAGA Diagnostics; Seagen; Summit pharmaceuticals; Taiho Oncology; Takeda; Takeda; Third Rock Ventures; UpToDate; Value Analytics Labs; Value Analytics Labs; Xilio Therapeutics; Zola
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); PMV Pharma; PureTech (Inst); Syndax
Travel, Accommodations, Expenses - Karkinos Healthcare; Karkinos Healthcare
Other Relationship - C2i genomics; CADEX Genomics; Parithera; Xact Robotics
 
Julia Moore
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Agenus; ALX Oncology; amplia; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Celgene; epsilon; insmed; ipsen; Mekanistic Therapeutics; Merck KGaA; Regeneron; Taiho Oncology
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); clasp (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); Nested Therapeutics (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Ipsen; Merck KGaA
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Actuate Therapeutics; Agenus; Amgen; Atreca; Boehringer Ingelheim; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Pfizer; Prelude Therapeutics; Quanta Therapeutics; Schrodinger; Sotio; Takeda; Wells Therapeutics; Zai Lab
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Arvinas; Genentech; Merck KGaA; Pfizer
 
Thomas Schuerpf
Employment - Incendia Therapeutics
Stock and Other Ownership Interests - Incendia Therapeutics - stock options; Scholar Rock
Research Funding - Incendia Therapeutics as employye
Travel, Accommodations, Expenses - Incendia Therapeutics - reimbursement for employee business travel
 
Irena Webster
Employment - Incendia Therapeutics
Stock and Other Ownership Interests - Alkermes; Incendia Therapeutics - options
Research Funding - Incendia Therapeutics as employee
Travel, Accommodations, Expenses - Incendia Therapeutics reimburses for employee business travel
 
Amy Mueller
Employment - Incendia Therapeutics
Stock and Other Ownership Interests - Incendia Therapeutics stock options - not owned
Research Funding - Incendia Therapeutics as employee
Patents, Royalties, Other Intellectual Property - Incendia Therapeutics provisional patent assigned to Incendia Therapeutics
Travel, Accommodations, Expenses - Incendia Therapeutics reimburses for travel to scientific meetings
 
Susan Macdonald
Employment - Incendia Therapeutics
Stock and Other Ownership Interests - Aldeyra Therapeutics; Incendia Therapeutics
Research Funding - incendia therapeutics
Patents, Royalties, Other Intellectual Property - I am listed as an inventor on at least one provisional patent application that has been assigned to Incendia Therapeutics
Travel, Accommodations, Expenses - Incendia Therapeutics
 
Joseph Eder
Employment - Incendia Therapeutics
Leadership - Incendia Therapeutics
Stock and Other Ownership Interests - Incendia Therapeutics - options
 
Alex Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)